Episomal Induced Pluripotent Stem Cells: Functional and Potential Therapeutic Applications

Abstract

The term episomal induced pluripotent stem cells (EiPSCs) refers to somatic cells that are reprogrammed into induced pluripotent stem cells (iPSCs) using non-integrative episomal vector methods. This reprogramming process has a better safety profile compared with integrative methods using viruses. There is a current trend toward using episomal plasmid reprogramming to generate iPSCs because of the improved safety profile. Clinical reports of potential human cell sources that have been successfully reprogrammed into EiPSCs are increasing, but no review or summary has been published. The functional applications of EiPSCs and their potential uses in various conditions have been described, and these may be applicable to clinical scenarios. This review summarizes the current direction of EiPSC research and the properties of these cells with the aim of explaining their potential role in clinical applications and functional restoration.

Keywords

Episomal induced pluripotent stem cells EiPSCs iPS therapeutic application

Introduction

Application of the reprogramming techniques first developed by Yamanaka et al.¹ has made possible the conversion of somatic cells to pluripotent stem cells that resemble embryonic stem cells (ESCs). ESCs have been touted as the “Holy Grail” for unrestricted regeneration because of their potential to differentiate into any cell lineage in the body and to replace damaged tissue. Opponents of this technique commonly cite the potential for unethical use or donation of ESCs, which are potential sources of life and embryo formation. With the development of a method to create induced pluripotent stem cells (iPSCs), it is possible to harness the regenerative properties of iPSCs, which resemble ESCs, yet without the ethical controversies associated with the sources of ESCs.

For research purposes, iPSCs can be readily cultured in the laboratory from various somatic cells. Somatic cells of various lineages have been shown to be capable of changing both their morphology and pluripotent potential through the overexpression of four main pluripotent factors: Oct3/4, Sox2, Klf4, and c-Myc (OSKM). The replacement of c-Myc and Klf4 by Nanog and Lin28 has also been shown to be possible when used in conjunction with Oct3/4 and Sox2 during the reprogramming of cells into iPSCs². Overexpression of Oct4, Sox2, and Nanog can also reprogram human fetal gut mesentery-derived cells into iPSCs³. Although Nanog is a dispensable reprogramming factor⁴, it has been reported to be essential for the ability for self-renewal⁵ and generation of stable iPSCs⁶. In some cases, such as adult mouse neural stem cells, expression of only one factor (Oct4) is sufficient for the generation of iPSCs⁷, even using episomal reprogramming⁸. A possible reason is the endogenous expression of Sox2, c-Myc, and Klf4 in neural stem cells. In addition, downregulation of p53 using knockdown⁹ and knockout¹⁰ methods can markedly improve the efficiency of iPSC generation¹¹, and only Oct4 and Sox2 are sufficient for iPSC generation under conditions of p53 loss¹². One possible mechanism to explain the suppression of iPSC generation by p53 is through the inhibition of the expression of Nanog and Oct4¹³. Certain somatic and adult stem cells, such as keratinocytes¹⁴ and dental pulp stem cells¹⁵, have a greater propensity to be reprogrammed into iPSCs compared with fibroblasts.

The introduction of these pluripotent reprogramming techniques can be divided into integrative and non-integrative methods. When first discovered, viral transduction was used for the insertion of the OSKM genes into the somatic cell genome. However, this may cause disruption to the host’s genome and, with the use of the proto-oncogene c-Myc, gene reactivation could increase the risk of transgene-derived tumor formation^16,17. Other methods have been used to reprogram somatic cells into iPSCs. In particular, non-integrative methods such as episomal plasmid delivery of pluripotent OSK genes without c-Myc have been touted as a safer alternative for iPSC generation^18,19. Episomal plasmid vectors are also combined with p53 knockdown to generate iPSCs^10,20,21. This review focuses on studies of the use of iPSCs generated using episomal plasmids, which are termed “episomal iPSCs” (EiPSCs) to reflect their origin.

Integrative Methods of iPSC Production

Potential issues with integrative methods of iPSC production include the inadvertent introduction of potentially harmful viral components that express certain oncogenes that may lead to tumor formation. Insertion of genes also carries the risk of disrupting the expression of host cell tumor suppressor genes, especially if the insertions occur in an open reading frame or alter the expression of oncogenes in close proximity¹⁷. Several viral systems have been introduced to circumvent this issue such as Cre-deletable²² or inducible lentiviruses, which reduce the risk of integration, although concerns have been raised about the use of viral vectors for therapeutic applications. Cre-deletable lentiviruses refer to a Cre recombinase-mediated deletion of a viral genome once integration is complete. This allows for the time-controlled integration, which is self-limiting and hence minimizes the chance of permanent viral genomic integration. Inducible lentivirus commonly refers to a tetracycline- or doxycycline-inducible expression system in lentiviruses, which allows the activation or deactivation of viral genomic DNA in the presence of tetracycline. This also provides some control over the duration of the viral genomic presence and, therefore, the risk of integration with the host genome.

Non-Integrative Methods of iPSC Production

The use of plasmids for the introduction of OSK pluripotent transcription factors has been described, and this method has been successful for reprogramming somatic and adult stem cells. The use of integration-defective viral delivery systems (adenoviruses²³, Sendai viruses²⁴), piggyBac systems²⁵, minicircle vectors²⁶, episomal delivery¹⁹, mRNA delivery²⁷, protein delivery²⁸, and chemical induction²⁹ in the production of iPSCs has been described. The piggyBac transposition system allows the direct cutting and pasting of sections of DNA to allow insertion and removal of certain sections. Specific deletion and insertion of reprogramming genes can be performed. Minicircle vectors are small circular plasmid derivatives that are freed from all prokaryotic vector parts or bacterial plasmid DNA. However, these are not in widespread use because of the intensive production process. The delivery of mRNA and protein can be much more costly for experimental purposes, and the mRNA or protein is not always inducible downstream. Chemical induction uses specific sets of chemicals and mutagens to allow the reprogramming of cells. By subjecting cells to a specific set of chemicals, researchers have shown that cells can be reprogrammed to their pluripotent state. However, this method is extremely laborious and has unknown safety parameters at present. Episomal plasmid delivery is cost effective, and the plasmid does not integrate when used with common transfection methods. This method provides an effective method for the delivery of plasmids into cells for reprogramming³⁰. The plasmids are readily available on multiple gene platforms and are removed from the host cell through cell division and serial dilution. The use of non-integrative methods of iPSC production has the advantage of producing iPSCs that are free of transgene integration. This has been confirmed by polymerase chain reaction (PCR) analysis, which shows no residual transgenes of viral origin³¹. For example, the Yamanaka group reported that no residual episomal plasmid DNA could be detected in clones after 11–20 passages²⁰.

Two components of the oriP and Epstein–Barr nuclear antigen-1 (EBNA-1) are also used widely in episomal plasmids^32

–38. Yu et al. reported that human iPSCs that are completely free of plasmids and transgene sequences could be derived from fibroblasts by a single transfection with oriP/EBNA-1-based episomal plasmids^39

–42. The footprint-free iPSCs make them safer for clinical application because of the loss of plasmids and transgenes. OriP/EBNA-1 plasmids have a wide host cell range for episomal reprogramming, and a single transfection of episomal plasmids is sufficient for iPSC generation. Compared with the original episomal plasmids without EBNA-1, oriP/EBNA-1 can improve the efficiency of iPSC generation⁴³ through the oriP/EBNA-1-mediated nuclear import and retention of vector DNA⁴⁴. It can replicate only once per cell cycle. Episomal DNA is lost from cells at a rate of 5% per cell generation because of defects in plasmid synthesis and partitioning⁴⁵. Subsequently, episome-free iPSCs can be easily harvested. Although plasmids appear in the first few cell passages immediately after transfection, many studies have used PCR analysis to show complete loss of plasmids and transgenes during extended cell culture^{20,39

–42,46

–58}. The time point of successful loss of episomes varies between different somatic cell types. The oriP/EBNA-1-based episomal plasmids have been proven to generate iPSCs very efficiently without the risk of transgenic sequences inserted into the somatic cell genome. Certain comments exist saying iPSCs generated using episomal plasmids with EBNA-1 expressed have residual episomal DNA. This does not appear to be true after reviewing the data presented by Yu et al.³⁹, where the group demonstrated that in fact that there were no residual plasmids and transgenes in iPSCs generated by EBNA-based plasmids using PCR and Southern blot analysis.

In an interesting experiment, the efficiency of reprogramming was compared between various methods for generating iPSCs. Reprogramming success rates were similarly high, at around 80%, with Sendai-viral, episomal, and lentivirus methods. mRNA methods alone were reported to have a lower success rate because of massive cell death and detachment. Episomal methods seem to be a good method for producing iPSCs, and the materials can be manufactured using current good manufacturing practice compatible processes (cGMP). As such, episomal methods remain very useful in the clinical setting⁵⁹.

Human EiPSC Sources

Multiple cell lineages from humans have been reprogrammed into iPSCs using episomal plasmids. Episomal plasmid reprogramming differs markedly from other forms of reprogramming techniques, such as retroviral transduction, and varied success rates have been reported. Recent trends include the increasing use of episomal plasmid methods for reprogramming various types of human cells for research use and potential clinical applications. The human cells reported to have been successfully reprogrammed into EiPSCs include fibroblasts, epithelial cells, keratinocytes, mononuclear cells from adult peripheral blood, cord blood cells, amniotic fluid stem cells, mesenchymal stromal cells, lymphoblasts, lamina propria progenitor cells from oral mucosa, and urothelial cells obtained from urine. A summary of these reported human EiPSC sources is shown in Table 1 ^{8,20,21,32

–43,47

–52,55,56,58,60

–207}. The variety of cell lineages that can be reprogrammed by episomal techniques demonstrates the versatility of this technique, which has been used in many laboratories around the world.

Table 1.

Summary of Reported Human EiPSC sources available in the Literature.

Type of cell	Source	Patient conditions	Method of transfection	Further differentiation	Author
Fibroblasts	Fetal foreskin	Healthy	Electroporation	N/A	Yu et al.^39,40, Matz and Adjave⁶², Tandon et al.⁶³, Tidball et al.⁶⁴, Kamath et al.⁶⁵, Kim et al.⁶⁶, Schmitt et al.⁶⁷, Mah et al.⁶⁸
Fibroblasts	Fetal foreskin	Healthy	Electroporation	CD235a⁺CD45⁻ leukocyte-free red blood cells	Dias et al.⁶⁹
Fibroblasts	Fetal foreskin	Healthy	Electroporation	Cardiomyocytes	Mehta et al.⁷⁰
Fibroblasts	Fetal foreskin	Healthy	Electroporation	Hepatocyte-like cells	Wruck and Adjave⁷¹
Fibroblasts; Fibroblasts	Fetal lung	Healthy	Poly(beta-amino ester) nanoparticles; Electroporation	Neuronal cells	Bhise et al.⁷²
Fibroblasts	Fetal foreskin	Healthy	Lipofectamine 3000 reagent	N/A	Skrzypczyk et al.⁷³
Fibroblasts	Fetal right musculus quadriceps femoris	Healthy	Lipofectamine 3000 reagent	N/A	Csobonyeiova et al.⁷⁴
Fibroblasts	Fetal foreskin	Homozygous α-thalassemia (−SEA/−SEA)	Electroporation	N/A	Tangprasittipap et al.⁷⁵
Fibroblasts	Fetal epidermal tissue from rim of open neural placode and spinal cord	Spina bifda aperta (SBA)	Electroporation	Neurospheres	Bamba et al.⁷⁶
Fibroblasts	Adult skin	Healthy	Electroporation	N/A	Bharathan et al.³⁶, Weltner et al.³⁷, Yu et al.⁴⁰, Wong et al.⁷⁷, Bang et al.⁷⁸, Hey et al.⁷⁹, Jaffer et al.⁸⁰, Trevisan et al.⁸¹, Fidan et al.⁸², Wang et al.⁸³, Chen et al.⁸⁴, Polanco et al.⁸⁵, Willmann et al.⁸⁶, Høffding et al.⁸⁷
Fibroblasts	Adult skin	Healthy	Electroporation; Lipofectamine 3000 reagent; Nucleofector system	N/A	Manzini et al.⁸⁸
Fibroblasts	Adult skin	Healthy	Electroporation	Neural stem cells	Capetian et al.⁸⁹
Fibroblasts	Adult skin	Healthy	Electroporation	Motor neurons	Hu et al.⁵¹
Fibroblasts	Adult skin	Healthy	Electroporation	Neural cells	Wang et al.⁹⁰
Fibroblasts	Adult skin	Healthy	Electroporation	Neural stem cells, motor neurons, cardiomyocytes, and fibroblasts	Requena et al.⁹¹
Fibroblasts	Adult skin	Healthy	Electroporation	Dopaminergic neurons and retinal pigment epithelial cells	Okita et al.²⁰
Fibroblasts	Adult skin	Healthy	Electroporation	Smooth muscle progenitor cells	Zhou et al.⁹²
Fibroblasts	Adult skin	Healthy	Electroporation	Retinal pigment epithelial cells	Li et al.⁹³
Fibroblasts	Adult skin	Healthy	Electroporation	Cardiomyocytes	Sequiera et al.⁹⁴
Fibroblasts	Adult skin	Healthy	FuGENE HD reagent	Hepatocyte-like and cardiac myocyte-like cells	Si-Tayeb et al.⁹⁵
Fibroblasts	Adult gingival tissues	Healthy	Electroporation	Periodontal cells	Yin et al.⁹⁶
Fibroblasts	Adult skin	Huntington’s disease	Electroporation	N/A	Tidball et al.²¹
Fibroblasts	Adult skin	Fibrodysplasia ossificans progressiva caused by a missense mutation in ACVR1 gene	Electroporation	N/A	Hayashi et al.³⁵
Fibroblasts	Adult skin	Spinocerebellar ataxia type 3	Electroporation	N/A	Hansen et al.^97,98
Fibroblasts	Adult skin	Frontotemporal dementia caused by mutations in microtubule-associated protein tau (MAPT) gene	Electroporation	N/A	Rasmussen et al.^99 –101
Fibroblasts	Adult skin	Maturity-onset diabetes of the young 4 and type ² diabetes mellitus caused by mutations in PDX1 gene	Electroporation	N/A	Wang et al.^52,102
Fibroblasts	Adult skin	Autosomal recessive Stargardt disease caused by compound heterozygous mutations in ABCA4 gene	Electroporation	N/A	Claassen et al.¹⁰³
Fibroblasts	Adult skin	X-Chromosomal disease	Electroporation	N/A	Hinz et al.¹²¹
Fibroblasts	Adult skin	Becker muscular dystrophy (BMD) caused by mutations in dystrophin gene on chromosome Xp21	Electroporation	N/A	Gowran et al.¹⁰⁵
Fibroblasts	Adult skin	Spinocerebellar ataxia type 3 (SCA3, also known as Machado-Joseph disease) caused by a CAG trinucleotide repeat expansion in ATXN3 gene	Electroporation	N/A	Hayer et al.¹⁰⁶
Fibroblasts	Adult skin	Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) caused by a heterozygous mutation in CSF1R gene	Electroporation	N/A	Hayer et al.¹⁰⁷
Fibroblasts	Adult skin	Healthy and kidney disease caused by an autosomal dominant mutation in HNF4A gene	Electroporation	N/A	Howden et al.¹⁰⁸
Fibroblasts	Adult skin	Prostate adenocarcinoma (PCa)	Electroporation	N/A	Kahounová et al.¹⁰⁹
Fibroblasts	Adult skin	Spinocerebellar ataxia type 3 (SCA3)	Electroporation	N/A	Ritthaphai et al.¹¹⁰
Fibroblasts	Adult skin	Dravet syndrome caused by a heterozygous R1525X mutation in SCN1A gene	Electroporation	N/A	Tanaka et al.¹¹¹
Fibroblasts	Adult skin	Mucoplysaccharydosis IIIA (MPSIIIA)	Electroporation	N/A	Vallejo et al.¹¹²
Fibroblasts	Adult skin	Mucopolysaccharydosis IIIB (MPSIIIB)	Electroporation	N/A	Vallejo-Diez et al.¹¹³
Fibroblasts	Adult skin	Late-onset non-syndromic retinitis pigmentosa caused by compound heterozygous mutations in CLN3 gene	Electroporation	N/A	Zhang et al.¹¹⁴
Fibroblasts	Adult skin	Autosomal recessive Alport syndrome (ARAS) caused by a homozygous COL4A3 mutation	Electroporation	N/A	Kuebler et al.¹¹⁵
Fibroblasts	Adult skin	X-linked Alport syndrome (XLAS) caused by hemizygous COL4A5 mutations in exon 41 or exon 46	Electroporation	N/A	Kuebler et al.¹¹⁶
Fibroblasts	Adult skin	Duchenne muscular dystrophy (DMD) lacking DMD exons 49 and 50	Electroporation	N/A	Spaltro et al.¹¹⁷
Fibroblasts	Adult skin	Leber’s hereditary optic neuropathy (LHON)	Electroporation	N/A	Hung et al.¹¹⁸
Fibroblasts	Adult skin	Low-grade steatosis	Electroporation	N/A	Kawala et al.¹¹⁹
Fibroblasts	Adult skin	Fibrodysplasia ossificans progressiva syndrome caused by a mutation in ACVR1 gene	Electroporation	N/A	Kim et al.¹²⁰
Fibroblasts	Adult skin	Alzheimer’s disease caused by mutations in PSEN1 gene	Electroporation	N/A	Li et al.^121,122, Poon et al.¹²³, Tubsuwan et al.¹²⁴
Fibroblasts	Adult skin	Familial Mediterranean Fever (FMF)	Electroporation	N/A	Fidan et al.¹²⁵
Fibroblasts	Adult skin	Turner syndrome (TS) caused by monosomy X	Electroporation	N/A	Luo et al.¹²⁶
Fibroblasts	Adult skin; Fetal skin	Retinitis pigmentosa; Severe combined immunodeficiency	Electroporation	N/A	Howden et al.¹²⁷
Fibroblasts	Adult skin	Ankylosing spondylitis; Sjögren’s syndrome; Systemic lupus erythematosus	Electroporation	Hematopoietic and mesenchymal lineages	Son et al.⁴⁷
Fibroblasts	Adult skin	Retinitis pigmentosa-11 caused by a dominant nonsense mutation in PRPF31 gene	Electroporation	Retinal organoids	McLenachan et al.¹²⁸
Fibroblasts	Adult skin	Rare neurodevelopmental disorders (NDDs)	Electroporation	Forebrain neurons	Bell et al.¹²⁹
Fibroblasts	Adult skin	Down syndrome	Electroporation	Neuronal cells	Briggs et al.¹³⁰
Fibroblasts	Adult skin	Alzheimer’s disease caused by mutations in PSEN1 gene	Electroporation	Mature neurons with amyloidogenic properties	Mahairaki et al.¹³¹
Fibroblasts	Adult skin	Low-density lipoprotein receptor (LDLR) deficiency familial hypercholesterolemia (FH)	Electroporation	Hepatocyte-like cells	Ramakrishnan et al.¹³²
Keratinocytes	Adult skin	Healthy	FuGENE HD reagent	N/A	Piao et al.¹³³
Mononuclear cells	Fetal peripheral blood	Healthy	Electroporation	N/A	Dowey et al.¹³⁴
Mononuclear cells	Neonatal peripheral blood and cord blood	Lung disease	Electroporation	N/A	Kamath et al.¹³⁵
Mononuclear cells	Adult peripheral blood	Healthy	Electroporation	N/A	Okita et al.⁴³, Wen et al.^136,137, Wang et al.^138,139, Su et al.¹⁴⁰, Tangprasittipap et al.¹⁴¹, Mack et al.¹⁴², Chou et al.¹⁴³
Mononuclear cells	Adult peripheral blood	Healthy	Electroporation	Cardiovascular progenitor cells	Hu et al.⁶¹
Mononuclear cells	Adult peripheral blood	Healthy	Electroporation	Ventricular cardiomyocyte	Weng et al.¹⁴⁴
Mononuclear cells	Adult peripheral blood	Healthy	Electroporation	Hepatocytes	Liu et al.¹⁴⁵
Mononuclear cells	Adult bone marrow	Healthy	Electroporation	Mesenchymal stem cells	TheinHan et al.¹⁴⁶
Mononuclear cells	Adult peripheral blood	Alzheimer’s disease	Electroporation	N/A	Wang et al.^147 –150
Mononuclear cells	Adult peripheral blood	Bipolar disorder (BD)	Electroporation	N/A	Wang et al.¹⁵¹
Mononuclear cells	Adult peripheral blood	Obsessive compulsive disorder (OCD)	Electroporation	N/A	Wang et al.¹⁵²
Mononuclear cells	Adult peripheral blood	Parkinson disease	Electroporation	N/A	Zhao et al.¹⁵³
Mononuclear cells	Adult peripheral blood	Complete dopa-responsive dystonia (DYT5) caused by a GCH1 mutation	Electroporation	N/A	Murakami et al.¹⁵⁴
Mononuclear cells	Adult peripheral blood	Hypertrophic cardiomyopathy caused by mutations in beta-myosin heavy chain (MYH7) gene	Electroporation	N/A	Ross et al.¹⁵⁵
Mononuclear cells	Adult peripheral blood	Sickle cell anemia (SCA)	Electroporation	CD34⁺CD45⁺ hematopoietic stem and progenitor cells	Junqueira Reis et al.¹⁵⁶
Mononuclear cells	Adult peripheral blood	Myocardial infarction	Electroporation	Cardiomyocytes	Malecki et al.¹⁵⁷
Mononuclear cells	Adult bone marrow	Healthy	Electroporation	Mesenchymal stem cells, adipocytes, chondrocytes, and osteoblasts	Tang et al.¹⁵⁸
Mononuclear cells	Adult peripheral blood and bone marrow	Myelodysplastic syndromes (MDS)	Electroporation	CD34⁺CD45⁺ hematopoietic stem and progenitor cells (HPC), and CD71⁺CD235a+ erythroid cells	Hsu et al.¹⁵⁹
Mononuclear cells	Fetal cord blood and neoplastic bone marrow; Adult patient	Healthy; Chronicmyeloid leukemia	Electroporation	CD34⁺CD43⁺ hematopoietic progenitors, CD34⁺CD31⁺CD43⁻ endothelial cells, and CD34⁺CD31⁻CD43⁻ mesenchymal cells; N/A	Hu et al.^41,160
Erythroblast	Adult peripheral blood	Healthy	Electroporation	N/A	Varga et al.¹⁶¹
Erythroblast	Adult peripheral blood	Ataxia-Telangiectasia (A-T) caused by compound heterozygous null mutations in ATM kinase gene at chromosome 11q22	Electroporation	Neural Stem Cells	Bhatt et al.^162,163
Cord blood CD34⁺ cells	Fetal cord blood	Healthy	Electroporation	N/A	Chou et al.⁴⁸, Meng et al.⁵⁶, Su et al.¹⁶⁴, Fernandes et al.^165 –167
Amniotic fluid cells	Fetal amniotic fluid	Healthy	Electroporation	N/A	Slamecka et al.¹⁶⁸, He et al.¹⁶⁹
Amniotic fluid cells	Fetal amniotic fluid	Healthy	Fugene HD reagent	Neural cells	Wilson et al.¹⁷⁰
Amniotic fluid cells	Fetal amniotic fluid	Trisomy 18 (18T)	Electroporation	N/A	Xing et al.¹⁷¹
Mesenchymal stromal cells	Fetal amnion	Healthy	Electroporation	N/A	Slamecka et al.¹⁷²
Mesenchymal stromal cells	Fetal femur	Healthy	Electroporation	N/A	Megges et al.⁶⁰
Mesenchymal stromal cells	Adult femur	Healthy	Electroporation	N/A	Göbel et al.¹⁷³, Foja et al.¹⁷⁴
Mesenchymal stromal cells	Adult subcutaneous fat	Healthy	Electroporation	N/A	Qu et al.¹⁷⁵
Mesenchymal stromal cells	Adult dental pulp	Healthy	Electroporation	Neural progenitor cells	Thekkeparambil Chandrabose et al.¹⁷⁶, Saitoh et al.¹⁷⁷
Mesenchymal stromal cells	Adult parotid gland	Squamous cell carcinoma of oral cavity	Electroporation	N/A	Yan et al.¹⁷⁸
Neural stem cells	Neonate	Healthy	Electroporation	N/A	Marchetto et al.⁵⁸
Neural stem cells	Fetal cortical tissue	Healthy	Electroporation	Neural cells	Zhou et al.⁸
Lymphoblast	Adult peripheral blood	Healthy	Electroporation	N/A	Schroter et al.¹⁷⁹
Lymphoblast	Adult peripheral blood	Healthy	Electroporation	Neurons, spinal motor neurons, and intestinal organoids	Barrett et al.¹⁸⁰
Lymphoblast	Adult peripheral blood	Parkinson’s disease	Electroporation	N/A	Kumar et al.⁴⁹
Lymphoblast	Adult peripheral blood	Alzheimer’s disease caused by a TREM2 missense mutation	Electroporation	N/A	Schroter et al.¹⁸¹
Lymphoblast	Adult peripheral blood	Alzheimer’s disease caused by a homozygous APOE4 allele mutation	Electroporation	N/A	Zulfiqar et al.^182,183
Lymphoblast	Adult peripheral blood	Alzheimer’s disease with different genotypes of a functional copy number variation in the AD risk gene CR1; AD with TREM2 p.R47H variant	Electroporation	N/A	Schröter et al.^184,185
Lymphoblast	Adult peripheral blood	APOE ∊3/∊3 genotype and expressing CR1 isoform F/F (low risk of Alzheimer’s disease)	Electroporation	N/A	Martins et al.¹⁸⁶
T cells	Adult peripheral blood	Healthy	Electroporation	Neuronal cells	Tsai et al.³³
T cells	Adult peripheral blood	Age-related macular degeneration	Electroporation	Retinal pigment epithelial cells	Chang et al.³⁴
B cells	Adult peripheral blood	Healthy	Electroporation	N/A	Choi et al.⁵⁵
B cells	Adult peripheral blood	Healthy	Electroporation	Hematopoietic, cardiac, neural, and hepatocyte-like lineages	Rajesh et al.⁴²
B cells	Adult peripheral blood	Parkinson’s disease	Electroporation	Neurospheres, and neural cells	Fujimori et al.¹⁸⁷
Lamina propria progenitor cells	Adult oral mucosal	Healthy	Electroporation	N/A	Howard-Jones et al.¹⁸⁸
Oral mucosa epithelial stem cells	Adult oral mucosal	Healthy	Electroporation	N/A	Alvisi et al.¹⁸⁹
Oral mucosa epithelial stem cells	Adult oral mucosal	Ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome caused by a R279H mutation in TP63 gene	Electroporation	N/A	Trevisan et al.¹⁹⁰
Urine cells	Adult urine	Healthy	Electroporation	N/A	Wang et al.¹⁹¹
Urine cells	Adult urine	Healthy	Electroporation	Hepatocyte-like cells	Si-Tayeb et al.¹⁹²
Urine cells	Adult urine	Multiple endocrine neoplasia type 1 (MEN1) (also termed Wermer syndrome) caused by mutations in tumor suppressor gene MEN1	Electroporation	N/A	Guo et al.¹⁹³
Urine cells	Adult urine	Type 2 long QT syndrome caused by a mutation in HERG A561P gene	Electroporation	Cardiomyocytes	Jouni et al.¹⁹⁴
Urine progenitor cells	Adult urine	Healthy	Lipofectamine 3000 reagent	N/A	Steichen et al.¹⁹⁵
Urine epithelial cells	Adult urine	Healthy	Electroporation	N/A	Ju et al.¹⁹⁶
Urine epithelial cells	Adult urine	Healthy	Electroporation	Hepatocytes	Sauer et al.⁵⁰
Urine epithelial cells	Adult urine	Phenylketonuria (PKU)	Electroporation	N/A	Qi et al.¹⁹⁷
Urine epithelial cells	Adult urine	Spinal muscular atrophy (SMA) caused by mutations in survival motor neuron 1 (SMN1) gene	Electroporation	Motor neurons	Zhou et al.¹⁹⁸
SIX2-positive renal cells	Adult urine	An African male expressing the CYP2D6 4/17 variant which confers intermediate drug metabolizing activity	Electroporation	N/A	Bohndorf et al.¹⁹⁹
Epicardium-derived cells	Adult atrial biopsy	Healthy	Electroporation	N/A	Paulitschek et al.²⁰⁰
Neonatal fibroblasts; Adult skin fibroblasts; Urine epithelial cells; Amniotic fluid cells	Neonatal and adult skin; adult urine	Healthy	PEI reagent	N/A	Drozd et al.³²
Fibroblasts; Urine epithelial cells	Adult skin; adult urine	Healthy	PEI reagent	Insulin producing cells	Walczak et al.³⁸
Fibroblasts; Mononuclear cells	Adult skin; Adult peripheral blood	Healthy	Electroporation	Cardiomyocytes, endothelial cells, and neuronal cell	Diecke et al.²⁰¹
Fibroblasts; Mononuclear cells	Adult skin; Adult peripheral blood	Kawasaki disease (KD)	Electroporation	Vascular endothelial cells	Ikeda et al.²⁰²
Mononuclear cells; Mesenchymal stromal cells	Adult peripheral blood and bone marrow	Healthy	Electroporation	N/A	Cheng et al.²⁰³
Fetal fibroblasts; Adult fibroblasts; Keratinocytes; Cord blood CD34⁺ cells	Fetal skin; Adult skin; Adult skin; Fetal cord blood	Healthy	Electroporation	N/A	Park et al.²⁰⁴
Fibroblasts; Cord blood CD34⁺ cells	Adult skin; Fetal cord blood	Healthy	Electroporation	Vascular progenitor cells	Park et al.²⁰⁵
Fibroblasts; Keratinocytes	Adult skin; Hair follicle	Timothy syndrome with cardiac arrhythmias	Lipofectamine 2000 reagent	Cardiomyocytes	Song et al.²⁰⁶
Cancer cells	Adult lung	Adenocarcinoma	X-tremeGENE transfection reagent	N/A	Zhao et al.²⁰⁷

The ease of obtaining several of the human cell types, such as those in peripheral blood or urine, for reprogramming make this method less invasive for donors, and there is an equivalent success rate for producing EiPSCs of similar nature. Obtaining EiPSCs from donors with known specific genetic manipulations also allows for the establishment of cell lines for further research, especially with regards to future developments of gene therapy for these specific conditions. Episomal plasmids have been used to generate EiPSCs from various somatic cells of differing origins. Human mesenchymal stromal cells have been developed into EiPSCs through the episomal plasmid-based expression of Oct4, Sox2, Nanog, Lin28, SV40LT, Klf4, and c-Myc⁶⁰. Other sources reported include human fetal foreskin fibroblasts, and CD34⁺ cells from cord and peripheral human blood, which shows that peripheral blood mononuclear cells may be a good source of cells for iPSC reprogramming especially because of the low invasiveness when obtaining samples.

Gene Delivery Methods

Delivery of plasmids into cells for reprogramming has been described. These methods include electroporation techniques (using Nucleofector kits), liposomal magnetofection, and Lipofectamine transfection reagents. Liposomal transfection using magnetofection²⁰⁸ or Lipofectamine refers to the delivery of plasmid DNA via liposomes and allows the merging of cationic liposomes carrying the DNA into the cells. Electroporation is the use of an electric current across cell membranes, which forcibly opens their channels to allow entry of reagents. This method has been described widely and has a higher rate of delivery efficiency but is known to cause cell damage²⁰⁹. The use of non-liposomal transfection reagents for episomal plasmid delivery, such as FuGENE HD, has also been reported to have good transfection efficiencies²¹⁰. The company produces a proprietary formula that is touted as non-liposomal but can still deliver DNA and plasmids into cells and therefore works as a transfection kit. Recent work has also shown promise in producing EiPSCs using small molecules instead of feeder cells. A cocktail of molecules has been described for the reprogramming of human somatic cells to iPSCs. These include the MEK inhibitor PD0325901, GSK3β inhibitor CHIR99021, TGF-β/activin/nodal receptor inhibitor A-83-01, ROCK inhibitor HA-100, and human leukemia inhibitory factor⁴⁰.

In Vivo Animal Model Applications

Cardiogenic Regeneration

Much attention has focused on the use of iPSCs in cardiac regeneration especially after cardiac infarction, which causes loss of cardiomyocytes that cannot regenerate and are replaced with scar tissue. Both EiPSCs and iPSCs have been differentiated into cardiomyocytes, which shows their potential use in both autologous and allogeneic therapies. A recent study demonstrated that allogeneic EiPSCs cultured from cynomolgus monkeys, when differentiated into cardiomyocytes and injected intramuscularly infarcted cardiac muscle, induced remuscularization of infarcted muscle tissue. Fibroblasts obtained from the monkeys were reprogrammed using episomal plasmids into EiPSCs, and the EiPSCs-derived cardiomyocytes were then injected into the infarcted cardiac muscle. After a clinical regimen of immunosuppression using methylprednisolone and tacrolimus, the hearts showed improvement in cardiac contractile function without any signs of rejection on postoperative week 12²¹¹. The results are promising in showing that direct application of EiPSCs-derived cardiomyocytes is possible. The local environment and conditions under which the EiPSCs were directly injected allowed for their direct use and differentiation according to clinical need. A diagram of the potential application for an EiPSCs-engineered cardiac cell sheet is shown in Fig. 1.

Figure 1.

The potential application for cardiac cell sheet strategies using EiPSC-derived cardiomyocytes. EiPSCs can be differentiated into cardiac progenitor cells, which are then induced to form cardiomyocytes in vitro. These cardiomyocytes can then be organized into a cell sheet and applied to damaged areas of cardiac muscle in vivo via intracoronary or intracardiac injections or epicardially by tissue-engineered cardiac patches. The cell sheets exhibit regenerative capabilities and induce the restoration of cardiac function after muscle damage.

One problem with bioengineered tissue is that it cannot be used to create a large structure, which requires thorough oxygenation, because of the lack of vascularization in the bioengineered construct. EiPSCs were reported to regenerate vascular tissue if some were first converted to patient-specific cardiovascular progenitor cells, which then differentiated into vascular smooth muscle cells to make up the vascular scaffold present in blood vessels. This new development heralds the potential for integration and creation of larger bioengineered constructs that can become vascularized. This suggests the potential ability to design whole organs with vascularized networks made from the patient’s cells, which are then attached using conventional surgical methods. This may allow the organ to be manufactured in the laboratory and vascularized⁶¹.

Peripheral Nerve Regeneration

EiPSCs have shown promise in promoting the regeneration of peripheral nerves in a mouse sciatic transection model²¹². Transection or neurotmesis of peripheral nerves is notoriously difficult to recover and usually leads to wasting of motor end plates, muscle atrophy, and functional loss, which markedly impairs the patient’s quality of life. In this mouse model, undifferentiated EiPSCs were applied to the transected ends of the sciatic nerves after coaptation of both ends by suturing. Compared with the negative control without cell administration, sciatic nerves treated with EiPSCs displayed significantly faster axonal regeneration and a ration of the degree of myelination to axonal diameter. These positive changes were similar to those observed in the ESC group, which acted as a positive control. The results of this study demonstrate the neuroregenerative potential of EiPSCs. One possible mechanism includes the increased expression of neutrotrophin-3, a neuronal growth factor, which can accelerate axonal regeneration and myelination. Direct application of EiPSCs to the site of injury and nerve transection presumably allowed the EiPSCs to act through a paracrine mechanism due to its direct effect and fast nature; they probably differentiate but rather, when applied to the environment, promoted sciatic nerve recovery through the upregulation of neutrotrophin-3 and subsequent secretion of neuronal growth factor by the EiPSCs themselves. The diagram in Fig. 2 shows a depiction of the actions of EiPSCs on mouse transected peripheral nerve regeneration.

Figure 2.

Topical application of EiPSCs to transected peripheral nerves. After surgical repair of transected peripheral nerves in a mouse sciatic nerve model, axonal regeneration was accelerated by topical application of EiPSCs to the site of injury. The increased production of neurotrophic factor-3 as a growth factor was one of the causes of acceleration of axonal growth and maintenance of muscle function and gait. Compared with negative controls without cell administrations, the regenerated axons exhibited a higher quality of myelination and more cells were obtained.

Ischemic Stroke Therapy

Mouse embryonic fibroblasts reprogrammed into EiPSCs using episomal plasmid transfection were delivered and used to treat mice in an ischemic stroke model²¹³. To avoid oncogenic and virus integration, while generating EiPSCs, two expression plasmids, Oct4 and Sox2, were repeatedly transfected into fibroblasts under hypoxic condition. The EiPSCs were first differentiated into neural precursor cells before being injected into the brain of mice after the induced ischemic stroke. The authors observed evidence of the differentiation of precursor cells into neurons and astrocytes. They concluded that these observed changes resulted in better behavioral recovery including locomotor activity, beam walking, and rotarod movement compared with control mice.

Smooth Muscle Regeneration

The use of EiPSCs in the regeneration of smooth muscle cells for the treatment of stress-induced urinary incontinence has also been described²¹⁴. Inadequate muscle sphincter function is a possible cause for urinary incontinence, and regeneration of smooth muscles at this sphincter may increase sphincter tone and hence urinary continence and control. The group here conducted experiments in rat urethral sphincters which were surgically weakened, resulting in urinary incontinence. Smooth muscle precursor cells were then differentiated from human EiPSCs and injected periurethrally to enhance muscle tone. Leak pressure and sphincter muscle electromyography were measured as markers of recovery. The group with the EiPSCs-derived smooth muscle injection showed recovery of the sphincter compared with the control without cell administration, which suggested that this method of treatment may be possible for restoration of urethral sphincter function.

EiPSCs currently have the potential for cardiac regeneration to replace damaged myocardium. The topical application of cells to regenerate a limited area appears promising, but reconstructing an entire cardiac structure requires further bioengineering advances to deliver blood supply to the entire organ. The use of EiPSCs in peripheral nerve regeneration can improve transected nerve recovery. Direct applications after surgical repair can enhance recovery through nerve growth factor secretion. In ischemic stroke therapy, EiPSCs may have potential for improving the recovery of damaged neural cells in the brain by differentiating into neurons and astrocytes, which should result in better motor recovery. EiPSCs can also play a role in regeneration of smooth muscle cells, leading to restoration of muscle sphincter function in urinary incontinence. A summary of the EiPSCs used in various functional studies is shown in Table 2 ^211

–214.

Table 2.

Summary of EiPSCs used in Various Functional Studies.

Type of cell	Animal model	Method of transfection	Differentiated cell type	Functional application	Author
Mouse fibroblasts	Mouse	FuGENE HD reagent	Neural precursor cells	Ischemic stroke therapy	Liu et al.²¹³
Mouse fibroblasts	Mouse	Lipofectamine 3000 reagent	N/A	Transected peripheral nerve recovery	Loh et al.²¹²
Primate fibroblasts	Cynomolgus monkey	Electroporation	Cardiomyocytes	Myocardial infarction recovery	Shiba et al.²¹¹
Human fibroblasts	Rat	Electroporation	Smooth muscle cells	Urethral spincter recovery	Wang et al.²¹⁴

Clinical Trials

Current clinical trials known at the time of writing this review all involve iPSCs derived from retroviral transduction. A trial of the replacement of retinal pigment epithelium cells (RPEs) in age-related macular degeneration (ARMD) was recently continued and is in progress. The human iPSCs used in this case were derived from retroviral reprogramming²¹⁵. Human iPSC-derived RPE cell sheets were generated without any artificial scaffolds, express typical RPE cell markers, form tight junctions that exhibit polarized secretion of growth factors, and show phagocytotic ability and gene-expression patterns similar to those of native RPE cells. The monolayer cell sheets have potential use as a graft for tissue replacement therapy for ARMD.

The trial was temporarily halted because spontaneous genetic mutations were found in the generation of iPSCs²¹⁶. The spontaneous mutations comprised six mutations, in which three genes had been deleted and another three nucleotides changed. One of the mutations was an “oncogene,” which has a low-risk link to cancer. None of these mutations were present in the patient’s original DNA makeup. The appearance of mutations was deemed to be either the result of the iPSC induction procedure or the presence at undetectable levels in the patient’s somatic skin cells initially. As the risk of carcinogenesis was low, the trial was continued as planned²¹⁷.

Currently registered trials focus on platelet generation for treating various anemias. However, the research group faced the problem of the mass production of platelets required for effective clinical use. Other trials involve the differentiation of dopaminergic neurons piloted for use in Parkinson’s disease. Retinal ganglion cells are also being used for treatment of glaucoma and optic neuropathies. Except for the current trial in Japan of the use of RPE cells for wet ARMD mentioned above, all of these trials are in the preclinical or animal model stages²¹⁸. Guidelines for further clinical trials for stem cell research involving patients and iPSCs were issued by the International Society for Stem Cell Research in 2016. These guidelines suggest that the donor cell procurement should be checked for iPSCs intended for use in human, and that these cells should be excluded from specialized reviews because they are now acknowledged to have different implications in the treatment of disease compared with human ESCs²¹⁹.

Safety

The evidence for the safety of the use of EiPSCs in animal models is only now emerging, and there is a paucity of evidence in this area. Mice given EiPSCs at the site of the transected sciatic nerve displayed no formation of tumors locally at the site of application²¹². Distant sites and major organs were also examined histologically for the presence of tumors after 1 year of follow-up. Normal behavior and health of the mice were recorded, and no ill effects of EiPSCs were reported in this group. Another study found no aberrant growths from differentiated EiPSCs that were added to primate hearts regeneration after a myocardial infarction²¹¹. Neither macroscopic nor microscopic analysis revealed any evidence of tumor formation at 12 weeks after transplantation of the EiPSCs-derived cardiomyocytes. One possible reason is that the EiPSCs used were completely differentiated, with minimal residual EiPSCs present remaining after grafting, which resulted in no tumor formation. Because viral or integrative reprogramming techniques may alter gene expression, the use of episomal reprogramming techniques in the production of EiPSCs may reduce the risk of tumor transformation. Further evidence is required to understand more about the safety of the use of EiPSCs and to substantiate the hypothesized mechanisms of action. One possible future direction is to compare the formation of tumors in two groups—undifferentiated EiPSCs and iPSCs generated from other methods such as retroviruses grafted onto recipients. The possible lack of tumor formation seen in EiPSC-transplanted groups from such a study design would provide evidence of its safety.

Yamanaka Cell Bank: A Future in Autologous and Allo-iPSC Therapy

With the recent establishment of the Yamanaka stem cell bank at the RIKEN BioResource Center in Japan, several human iPSC cell lines have been produced in preparation for future research or clinical application. A switch to episomal methods of iPSC production is evident from the most recent human iPSC cell lines formed at the Yamanaka stem cell bank²²⁰. As mentioned previously, to enable use of the cells clinically, particular attention should be paid to the methods of iPSC production that favor episomal methods. The Yamanaka stem cell bank has successfully produced multiple human cell lines of EiPSCs using transformation of human cells from various types. EiPSCs have been produced from human skin fibroblasts (cell numbers HPS0076, HPS0077)^221,222, human cord blood (cell numbers HPS0328, HPS0331), and human peripheral blood (cell number HPS0360)⁴³. Other than the two initial cell lines produced from human, which were obtained using retroviral transduction without c-Myc, the five more recently developed human EiPSC cell lines were produced purely via episomal vectors. A diagram showing the potential for an EiPSC bank is depicted in Fig. 3.

Figure 3.

The potential for an EiPSC bank. The pluripotent potential of EiPSCs allows them to differentiate into various cell lineages for repair and regeneration. Fibroblasts from healthy donors can be harvested and reprogrammed into EiPSCs and stored in a cell bank. These EiPSCs can then be differentiated into various cell lineages for repair and regeneration according to the needs of individual patients. So far, these cells include cardiomyocytes, hematopoietic progenitor cells, neural cells, adipocytes, and pancreatic islet cells. Each of these cells can be used to replace damaged cells in patients and provide a novel therapeutic potential for each clinical scenario. For any allogeneic transfer of EiPSCs, MHC mismatch typing can first be performed to minimize any chance of MHC mismatch incompatibility before selecting the least antigenic EiPSC bank sample to be transferred to the patient.

The immunogenicity of iPSCs generated remains an unknown area of research. A recent study showed a possible immune response toward smooth muscle cells derived from iPSCs but not the RPE from iPSCs²²³. Possible strategies for bypassing a possible immune response include the development of humanized iPSCs-derived RPE cells for transplantation. In a humanized mouse model, Zhao et al. found that the smooth muscle cells induced a strong antigenic response by the host’s immune system which was not evident when RPE cells were used. The potential use of immunosuppression must be considered for the clinical use and clinical trials of iPSCs. If there is evidence of rejection of tissue as for a foreign host, immunosuppressants should be administered when the cells are delivered to the recipient. The use of iPSCs for treating Parkinson’s disease has been reported in Japan. However, certain clinical considerations, such as the safety and therapeutic use of iPSCs in patients with Parkinson’s disease, are needed. Clinical trials are underway for examining this aspect of iPSC use and treatment. Current rapid integration into its clinical use should continue to surface within the next few years²²⁴.

Conclusion

The future of EiPSCs lies in the increasing trend for the use of cell therapy in the treatment of various diseases because of their regenerative properties. Differentiating these cells before use or their direct application requires further investigation. The immunogenicity of allogeneic EiPSCs will also need to be determined for the tissue both derived and differentiated from these cells.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from Chang Gung Medical Foundation, Chang Gung Memorial Hospital, Taiwan (CMRPG1F0082, CMRPG3F1431, CMRPG1H0081 and CMRPG1H0082) and Ministry of Science and Technology, Taiwan (MOST 108-2314-B-182A-009-).

ORCID iD

Aline Yen Ling Wang

References

Takahashi

Yamanaka

. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.

Vodyanik

Smuga-Otto

Antosiewicz-Bourget

Frane

Tian

Nie

Jonsdottir

Ruotti

Stewart

Slukvin

, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920.

Zhao

Lan

Lee

Chen

Lin

Yao

. Generation of human-induced pluripotent stem cells from gut mesentery-derived cells by ectopic expression of OCT4/SOX2/NANOG. Cell Reprogram. 2010;12(3):237–247.

Schwarz

Bar-Nur

Silva

Hochedlinger

. Nanog is dispensable for the generation of induced pluripotent stem cells. Curr Biol. 2014;24(3):347–350.

Olariu

Lövkvist

Sneppen

Nanog, Oct4 and Tet1 interplay in establishing pluripotency. Sci Rep. 2016;6:25438.

Sumer

Liu

Malaver-Ortega

Lim

Khodadadi

Verma

. NANOG is a key factor for induction of pluripotency in bovine adult fibroblasts. J Anim Sci. 2011;89(9):2708–2716.

Kim

Sebastiano

Araúzo-Bravo

Sasse

Gentile

Ruau

Ehrich

van den Boom

Meyer

, et al. Oct4-induced pluripotency in adult neural stem cells. Cell. 2009;136(3):411–419.

Zhou

Liu

Feng

Wang

Jiang

Zhang

Lan

. Survivin improves reprogramming efficiency of human neural progenitors by single molecule OCT4. Stem Cells Int. 2016. doi:10.1155/2016/4729535.

Zhao

Yin

Qin

Zhu

Liu

Yang

Zhang

Xiang

Hou

Song

Liu

, et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell. 2008;3(5):475–479.

10.

Hong

Takahashi

Ichisaka

Aoi

Kanagawa

Nakagawa

Okita

Yamanaka

. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009;460(7259):1132–1135.

11.

Feng

Lewis

Yuan

Zhang

Cheng

Miao

Yuan

, et al. The p53-PUMA axis suppresses iPSC generation. Nat Commun. 2013;4:2174.

12.

Lin

. p53 switches off pluripotency on differentiation. Stem Cell Res Ther. 2017;8(1):44.

13.

Solozobova

Blattner

. p53 in stem cells. World J Biol Chem. 2011;2(9):202–214.

14.

Aasen

Raya

Barrero

Garreta

Consiglio

Gonzalez

Vassena

Bilić

Pekarik

Tiscornia

Edel

, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol. 2008;26(11):1276–1284.

15.

Yan

Qin

Tuan

Shi

Huang

. iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. Stem Cells Dev. 2010;19(4):469–480.

16.

Aoi

Yae

Nakagawa

Ichisaka

Okita

Takahashi

Chiba

Yamanaka

. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science. 2008;321(5889):699–702.

17.

Okita

Ichisaka

Yamanaka

. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313–317.

18.

Okita

Nakagawa

Hyenjong

Ichisaka

Yamanaka

. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322(5903):949–953.

19.

Okita

Hong

Takahashi

Yamanaka

. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc. 2010;5(3):418–428.

20.

Okita

Matsumura

Sato

Okada

Morizane

Okamoto

Hong

Nakagawa

Tanabe

Tezuka

Shibata

, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8(5):409–412.

21.

Tidball

Neely

Chamberlin

Aboud

Kumar

Han

Bryan

Aschner

Ess

Bowman

. Genomic instability associated with p53 knockdown in the generation of Huntington’s disease human induced pluripotent stem cells. PLoS One. 2016;11(3):e0150372.

22.

Hanna

Wernig

Markoulaki

Sun

Meissner

Cassady

Beard

Brambrink

Townes

Jaenisch

. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318(5858):1920–1923.

23.

Zhou

Freed

. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells. 2009;27(11):2667–2674.

24.

Fusaki

Ban

Nishiyama

Saeki

Hasegawa

. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):348–362.

25.

Woltjen

Michael

Mohseni

Desai

Mileikovsky

Hämäläinen

Cowling

Wang

Liu

Gertsenstein

Kaji

, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458(7239):766–770.

26.

Jia

Wilson

Sun

Gupta

Huang

Panetta

Chen

Robbins

Kay

Longaker

, et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods. 2010;7(3):197–199.

27.

Warren

Manos

Ahfeldt

Loh

Lau

Ebina

Mandal

Smith

Meissner

Daley

, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618–630.

28.

Kim

Moon

Chung

Chang

Han

Yang

Cha

Lanza

Kim

. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4(6):472–476.

29.

Wei

Zhu

Shi

Lin

Hao

Hayek

Deng

Ding

. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell. 2009;4(1):16–19.

30.

Vdovin

Lupatov

Kholodenko

Yarygin

. Comparison of the efficiency of viral transduction and episomal transfection in human fibroblast reprogramming. Bull Exp Biol Med. 2015;160(1):123–128.

31.

O’Doherty

Greiser

Wang

. Nonviral methods for inducing pluripotency to cells. Biomed Res Int. 2013;2013:705902.

32.

Drozd

Walczak

Piaskowski

Stoczynska-Fidelus

Rieske

Grzela

. Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system. Stem Cell Res Ther. 2015;6(1):122.

33.

Tsai

Chang

Lee

Yang

Lin

Chang

Shih

Chen

. Differentiation of blood T cells: reprogramming human induced pluripotent stem cells into neuronal cells. J Chin Med Assoc. 2015;78(6):353–359.

34.

Chang

Hung

Yang

Cheng

Liao

Woung

Tsai

Hsu

Lin

Liu

, et al. The generation of induced pluripotent stem cells for macular degeneration as a drug screening platform: identification of curcumin as a protective agent for retinal pigment epithelial cells against oxidative stress. Front Aging Neurosci. 2014;6:191.

35.

Hayashi

Hsiao

Sami

Lancero

Schlieve

Nguyen

Yano

Nagahashi

Ikeya

Matsumoto

Nishimura

, et al. BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence. Proc Natl Acad Sci U S A. 2016;113(46):13057–13062.

36.

Bharathan

Manian

Aalam

Palani

Deshpande

Pratheesh

Srivastava

Velayudhan

. Systematic evaluation of markers used for the identification of human induced pluripotent stem cells. Biol Open. 2017;6(1):100–108.

37.

Weltner

Balboa

Katayama

Bespalov

Krjutškov

Jouhilahti

Trokovic

Kere

Otonkoski

. Human pluripotent reprogramming with CRISPR activators. Nat Commun. 2018;9(1):2643.

38.

Walczak

Drozd

Stoczynska-Fidelus

Rieske

Grzela

. Directed differentiation of human iPSC into insulin producing cells is improved by induced expression of PDX1 and NKX6.1 factors in IPC progenitors. J Transl Med. 2016;14(1):341.

39.

Smuga-Otto

Tian

Stewart

Slukvin

Thomson

. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324(5928):797–801.

40.

Chau

Vodyanik

Jiang

. Efficient feeder-free episomal reprogramming with small molecules. PLoS One. 2011;6(3):e17557.

41.

Suknuntha

Tian

Montgomery

Choi

Stewart

Thomson

Slukvin

. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011;117(14):e109–e119.

42.

Rajesh

Dickerson

Brown

Thomson

Seay

. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood. 2011;118(7):1797–1800.

43.

Okita

Yamakawa

Matsumura

Sato

Amano

Watanabe

Goshima

Yamanaka

. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013;31(3):458–466.

44.

Middleton

Sugden

. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol. 1994;68(6):4067–4071.

45.

Nanbo

Sugden

. The coupling of synthesis and partitioning of EBV’s plasmid replicon is revealed in live cells. EMBO J. 2007;26(19):4252–4262.

46.

Ross

Fraser

Bagnall

Semsarian

. Peripheral blood derived induced pluripotent stem cells (iPSCs) from a female with familial hypertrophic cardiomyopathy. Stem Cell Res. 2017;20:76–79.

47.

Son

Lee

Jeon

Seol

Kim

Chang

Cho

. Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease. Exp Mol Med. 2016;48:e232.

48.

Chou

Mali

Huang

Dowey

Resar

Zou

Zhang

Tong

Cheng

. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. 2011;21(3):518–529.

49.

Kumar

Curran

Glahn

Blangero

. Utility of lymphoblastoid cell lines for induced pluripotent stem cell generation. Stem Cells Int. 2016;2016(9):1–20.

50.

Sauer

Tchaikovskaya

Wang

Zhang

Tar

Polgar

Ding

Guha

Fox

Roy-Chowdhury

, et al. Human urinary epithelial cells as a source of engraftable hepatocyte-like cells using stem cell technology. Cell Transplant. 2016;25(12):2221–2243.

51.

Xiong

Chen

Hou

Qiu

Fang

Zhang

. Derivation, expansion, and motor neuron differentiation of human-induced pluripotent stem cells with non-integrating episomal vectors and a defined xenogeneic-free culture system. Mol Neurobiol. 2016;53(3):1589–1600.

52.

Wang

Chen

Burtscher

Sterr

Hieronimus

Machicao

Staiger

Häring

Lederer

Meitinger

Lickert

. Generation of a human induced pluripotent stem cell (iPSC) line from a patient with family history of diabetes carrying a C18 R mutation in the PDX1 gene. Stem Cell Res. 2016;17(2):292–295.

53.

Gallego Romero

Pavlovic

Hernando-Herraez

Zhou

Ward

Banovich

Kagan

Burnett

Huang

Mitrano

Chavarria

, et al. A panel of induced pluripotent stem cells from chimpanzees: a resource for comparative functional genomics. Elife. 2015;4:1–29.

54.

Jung-Klawitter

Blau

Sebe

Ebersold

Göhring

Opladen

Generation of an iPSC line from a patient with tyrosine hydroxylase (TH) deficiency: TH-1 iPSC. Stem Cell Res. 2016;17(3):580–583.

55.

Choi

Liu

Chaudhari

Kim

Cheng

Feng

Sharkis

Jang

. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood. 2011;118(7):1801–1805.

56.

Meng

Neises

Payne

Ritter

Gridley

Wang

Sheng

Lau

Baylink

Zhang

. Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther. 2012;20(2):408–416.

57.

Pollini

Loffredo

Cardano

Conti

Lattante

Notarangelo

Sabatelli

Provenzani

. Generation and characterization of a human iPSC line from an ALS patient carrying the Q66K-MATR3 mutation. Stem Cell Res. 2018;33:146–150.

58.

Marchetto

Yeo

Kainohana

Marsala

Gage

Muotri

. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS One. 2009;4(9):e7076.

59.

Schlaeger

Daheron

Brickler

Entwisle

Chan

Cianci

DeVine

Ettenger

Fitzgerald

Godfrey

Gupta

, et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015;33(1):58–63.

60.

Megges

Oreffo

Adjaye

. Episomal plasmid-based generation of induced pluripotent stem cells from fetal femur-derived human mesenchymal stromal cells. Stem Cell Res. 2016;16(1):128–132.

61.

Wang

Jiao

Liu

Zhao

Zhou

Zhang

Forde

Wang

Baylink

, et al. Patient-specific cardiovascular progenitor cells derived from integration-free induced pluripotent stem cells for vascular tissue regeneration. Biomaterials. 2015;73:51–59.

62.

Matz

Adjaye

. Episomal-based generation of an iPS cell line from human fetal foreskin fibroblasts. Stem Cell Res. 2016;16(1):67–69.

63.

Tandon

Brändl

Baryshnikova

Landshammer

Steenpaß

Keminer

Pless

Müller

. Generation of two human isogenic iPSC lines from fetal dermal fibroblasts. Stem Cell Res. 2018;33:120–124.

64.

Tidball

Swaminathan

Dang

Parent

. Generating loss-of-function iPSC lines with combined CRISPR indel formation and reprogramming from human fibroblasts. Bio Protoc. 2018;8(7):e2794.

65.

Kamath

Ternes

McGowan

English

Mallampalli

Moy

. Efficient method to create integration-free, virus-free, Myc and Lin28-free human induced pluripotent stem cells from adherent cells. Future Sci OA. 2017;3(3):FSO211.

66.

Kim

Heo

Lee

Seo

Chung

. High-efficiency generation of induced pluripotent stem cells from human foreskin fibroblast cells using the Sagunja-tang herbal formula. BMC Complement Altern Med. 2017;17(1):529.

67.

Schmitt

Morales

Schmitz

EMH

Hawkins

Lizama

Zape

Hsiao

Zovein

. Fluorescent tagged episomals for stoichiometric induced pluripotent stem cell reprogramming. Stem Cell Res Ther. 2017;8(1):132.

68.

Mah

Wang

Liao

Prigione

Jozefczuk

Lichtner

Wolfrum

Haltmeier

Flöttmann

Schaefer

Hahn

, et al. Molecular insights into reprogramming-initiation events mediated by the OSKM gene regulatory network. PLoS One. 2011;6(8):e24351.

69.

Dias

Gumenyuk

Kang

Vodyanik

Thomson

Slukvin

. Generation of red blood cells from human induced pluripotent stem cells. Stem Cells Dev. 2011;20(9):1639–1647.

70.

Mehta

Chung

Iskandar

Atan

Wei

Dusting

Sun

Wong

Shim

. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc Res. 2011;91(4):577–586.

71.

Wruck

Adjaye

. Human pluripotent stem cell derived HLC transcriptome data enables molecular dissection of hepatogenesis. Sci Data. 2018;5:180035.

72.

Bhise

Wahlin

Zack

Green

. Evaluating the potential of poly(beta-amino ester) nanoparticles for reprogramming human fibroblasts to become induced pluripotent stem cells. Int J Nanomedicine. 2013;8:4641–4658.

73.

Skrzypczyk

Giri

Bader

. Generation of induced pluripotent stem cell line from foreskin fibroblasts. Stem Cell Res. 2016;17(3):572–575.

74.

Csobonyeiova

Krajciova

Nicodemou

Polak

Danisovic

. Induction of pluripotency in long-term cryopreserved human neonatal fibroblasts in feeder-free condition. Cell Tissue Bank. 2017;18(1):45–52.

75.

Tangprasittipap

Satirapod

Jittorntrum

Lertritanan

Anurathaphan

Phanthong

Borwornpinyo

Kitiyanant

Hongeng

. Generation of iPSC line MU011.A-hiPS from homozygous alpha-thalassemia fetal skin fibroblasts. Stem Cell Res. 2015;15(3):506–509.

76.

Bamba

Nonaka

Sasaki

Shofuda

Kanematsu

Suemizu

Higuchi

Pooh

Kanemura

Okano

Yamasaki

. Generation of induced pluripotent stem cells and neural stem/progenitor cells from newborns with spina bifida aperta. Asian Spine J. 2017;11(6):870–879.

77.

Wong

RCB

Hung

Jackson

Singh

Khan

Liang

Kearns

Nguyen

Conquest

Daniszewski

Hewitt

, et al. Generation of a human induced pluripotent stem cell line CERAi001-A-6 using episomal vectors. Stem Cell Res. 2017;22:13–15.

78.

Bang

Choi

Lee

Park

Jeong

Chung

. Optimization of episomal reprogramming for generation of human induced pluripotent stem cells from fibroblasts. Anim Cells Syst (Seoul). 2018;22(2):132–139.

79.

Hey

CAB

Saltõkova

Bisgaard

Møller

. Comparison of two different culture conditions for derivation of early hiPSC. Cell Biol Int. 2018;42(11):1467–1473.

80.

Jaffer

Goh

Abbasian

Nathwani

. Mbd3 promotes reprogramming of primary human fibroblasts. Int J Stem Cells. 2018;11(2):235–241.

81.

Trevisan

Desole

Costanzi

Lavezzo

Palù

Barzon

. Reprogramming methods do not affect gene expression profile of human induced pluripotent stem cells. Int J Mol Sci. 2017;18(1):206.

82.

Fidan

Ebrahimi

Çağlayan

ÖH

Özçimen

Önder

. Transgene-free disease-specific iPSC generation from fibroblasts and peripheral blood mononuclear cells. Methods Mol Biol. 2016;1353:215–231.

83.

Wang

Hung

Thissen

Kingshott

Wong

. Binary colloidal crystals (BCCs) as a feeder-free system to generate human induced pluripotent stem cells (hiPSCs). Sci Rep. 2016;6. doi:10.1038/srep36845.

84.

Chen

Gulbranson

Hou

Bolin

Ruotti

Probasco

Smuga-Otto

Howden

Diol

Propson

Wagner

, et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods. 2011;8(5):424–429.

85.

Polanco

Wang

Zhou

Wolvetang

Mason

Wells

Kolle

Grimmond

Bertoncello

O’Brien

, et al. Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency. Stem Cells. 2013;31(8):1498–1510.

86.

Willmann

Hemeda

Pieper

Lenz

Qin

Joussen

Sontag

Wanek

Denecke

Schüler

Zenke

, et al. To clone or not to clone? Induced pluripotent stem cells can be generated in bulk culture. PLoS One. 2013;8(5):e65324.

87.

Hoffding

Hyttel

. Ultrastructural visualization of the Mesenchymal-to-Epithelial Transition during reprogramming of human fibroblasts to induced pluripotent stem cells. Stem Cell Res. 2015;14(1):39–53.

88.

Manzini

Viiri

Marttila

Aalto-Setälä

. A comparative view on easy to deploy non-integrating methods for patient-specific iPSC production. Stem Cell Rev. 2015;11(6):900–908.

89.

Capetian

Azmitia

Pauly

Krajka

Stengel

Bernhardi

Klett

Meier

Seibler

Stanslowsky

Moser

, et al. Plasmid-based generation of induced neural stem cells from adult human fibroblasts. Front Cell Neurosci. 2016;10:245.

90.

Wang

Hao

Bai

Wang

Liu

Zhou

. Efficient derivation of human induced pluripotent stem cells with a c-myc-free non-integrating episomal vector. J Genet Genomics. 2016;43(3):161–164.

91.

Requena

Alvarez-Palomo

Codina-Pascual

Delgado-Morales

Moran

Esteller

Sal

Juan

Boronat Barado

Consiglio

Bogle

, et al. Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human tlr3 affecting proper innate immune response signaling. Stem Cells. 2019;37(4):476–488.

92.

Zhou

Kang

Wen

Briggs

Sebastiano

Pederson

Chen

. Do induced pluripotent stem cell characteristics correlate with efficient in vitro smooth muscle cell differentiation? A comparison of three patient-derived induced pluripotent stem cell lines. Stem Cells Dev. 2018;27(20):1438–1448.

93.

Sun

Liu

Jin

Hao

Han

Sun

Zhang

, et al. Transcriptional reactivation of OTX2, RX1 and SIX3 during reprogramming contributes to the generation of RPE cells from human iPSCs. Int J Biol Sci. 2016;12(5):505–517.

94.

Sequiera

Mehta

Ooi

Shim

. Ontogenic development of cardiomyocytes derived from transgene-free human induced pluripotent stem cells and its homology with human heart. Life Sci. 2013;92(1):63–71.

95.

Si-Tayeb

Noto

Sepac

Sedlic

Bosnjak

Lough

Duncan

. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol. 2010;10(1):81.

96.

Yin

Liu

Wen

Luan

. Generation and periodontal differentiation of human gingival fibroblasts-derived integration-free induced pluripotent stem cells. Biochem Biophys Res Commun. 2016;473(3):726–732.

97.

Hansen

Borland

Hasholt

Tümer

Nielsen

Rasmussen

Nielsen

Stummann

Fog

Hyttel

. Generation of spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cell line SCA3.B11. Stem Cell Res. 2016;16(3):589–592.

98.

Hansen

Borland

Hasholt

Tümer

Nielsen

Rasmussen

Nielsen

Stummann

Fog

Hyttel

. Generation of spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cell line SCA3.A11. Stem Cell Res. 2016;16(3):553–556.

99.

Rasmussen

Hjermind

Hasholt

Waldemar

Nielsen

Clausen

Hyttel

Holst

. Induced pluripotent stem cells (iPSCs) derived from a patient with frontotemporal dementia caused by a R406 W mutation in microtubule-associated protein tau (MAPT). Stem Cell Res. 2016;16(1):75–78.

100.

Rasmussen

Hjermind

Hasholt

Waldemar

Nielsen

Clausen

Hyttel

Holst

. Induced pluripotent stem cells (iPSCs) derived from a patient with frontotemporal dementia caused by a P301 L mutation in microtubule-associated protein tau (MAPT). Stem Cell Res. 2016;16(1):70–74.

101.

Rasmussen

Hjermind

Hasholt

Waldemar

Nielsen

Clausen

Hyttel

Holst

. Induced pluripotent stem cells (iPSCs) derived from a pre-symptomatic carrier of a R406 W mutation in microtubule-associated protein tau (MAPT) causing frontotemporal dementia. Stem Cell Res. 2016;16(1):105–109.

102.

Wang

Chen

Burtscher

Sterr

Hieronimus

Machicao

Staiger

Häring

Lederer

Meitinger

Lickert

. Generation of a human induced pluripotent stem cell (iPSC) line from a patient carrying a P33 T mutation in the PDX1 gene. Stem Cell Res. 2016;17(2):273–276.

103.

Claassen

Zhang

Chen

Moon

Lamey

Thompson

McLaren

De Roach

McLenachan

Chen

. Generation of the induced pluripotent stem cell line from a patient with autosomal recessive ABCA4-mediated Stargardt Macular Dystrophy. Stem Cell Res. 2019;34:101352.

104.

Hinz

Hoekstra

Watanabe

Posthuma

Heine

. Generation of isogenic controls for in vitro disease modelling of X-chromosomal disorders. Stem Cell Rev. 2019;15(2):276–285.

105.

Gowran

Spaltro

Casalnuovo

Vigorelli

Spinelli

Castiglioni

Rovina

Paganini

Di Segni

Gervasini

Nigro

, et al. Generation of induced pluripotent stem cells from a Becker muscular dystrophy patient carrying a deletion of exons 45-55 of the dystrophin gene (CCMi002BMD-A-9 ▵45-55). Stem Cell Res. 2018;28:21–24.

106.

Hayer

Schelling

Huebener-Schmid

Weber

Hauser

Schöls

Generation of an induced pluripotent stem cell line from a patient with spinocerebellar ataxia type 3 (SCA3): HIHCNi002-A. Stem Cell Res. 2018;30:171–174.

107.

Hayer

Schelling

Hoeflinger

Hauser

Schöls

Generation of an induced pluripotent stem cell line from a patient with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): HIHCNi003-A. Stem Cell Res. 2018;30:206–209.

108.

Howden

Thomson

Little

. Simultaneous reprogramming and gene editing of human fibroblasts. Nat Protoc. 2018;13(5):875–898.

109.

Kahounová

Slabáková

Binó

Remšík

Fedr

Bouchal

Kurfűrstová

Vrtěl

Študent

Jurečková

Porokh

, et al. Generation of human iPSCs from human prostate cancer-associated fibroblasts IBPi002-A. Stem Cell Res. 2018;33:255–259.

110.

Ritthaphai

Wattanapanitch

Pithukpakorn

Heepchantree

Soi-Ampornkul

Mahaisavariya

Triwongwaranat

Pattanapanyasat

Vatanashevanopakorn

. Derivation of an induced pluripotent stem cell line (MUSIi004-A) from dermal fibroblasts of a 48-year-old spinocerebellar ataxia type 3 patient. Stem Cell Res. 2018;30:113–116.

111.

Tanaka

Higurashi

Shirasu

Yasunaga

Moreira

Okano

Hirose

. Establishment of a human induced stem cell line (FUi002-A) from Dravet syndrome patient carrying heterozygous R1525X mutation in SCN1A gene. Stem Cell Res. 2018;31:11–15.

112.

Vallejo

Fleischer

Martín

Sánchez

Palomino

Bachiller

Generation of two induced pluripotent stem cells lines from Mucopolysaccharydosis IIIA patient: IMEDEAi004-A and IMEDEAi004-B. Stem Cell Res. 2018;32:110–114.

113.

Vallejo-Diez

Fleischer

Martín-Fernández

Sánchez-Gilabert

Bachiller

. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient. Stem Cell Res. 2018;33:180–184.

114.

Zhang

Chen

Lamey

Thompson

McLaren

De Roach

Chen

McLenachan

. Generation of an induced pluripotent stem cell line from a patient with non-syndromic CLN3-associated retinal degeneration and a coisogenic control line. Stem Cell Res. 2018;29:245–249.

115.

Kuebler

Aran

Miquel-Serra

Muñoz

Ars

Bullich

Furlano

Torra

Marti

Veiga

Raya

. Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS). Stem Cell Res. 2017;25:1–5.

116.

Kuebler

Aran

Miquel-Serra

Muñoz

Ars

Bullich

Furlano

Torra

Marti

Veiga

Raya

. Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS). Stem Cell Res. 2017;25:291–295.

117.

Spaltro

Vigorelli

Casalnuovo

Spinelli

Castiglioni

Rovina

Paganini

Di Segni

Nigro

Gervasini

Pompilio

, et al. Derivation of the Duchenne muscular dystrophy patient-derived induced pluripotent stem cell line lacking DMD exons 49 and 50 (CCMi001DMD-A-3, 49, 50). Stem Cell Res. 2017;25:128–131.

118.

Hung

Van Bergen

Jackson

Liang

Mackey

Hernández

Lim

Hewitt

Trounce

Pébay

Wong

. Study of mitochondrial respiratory defects on reprogramming to human induced pluripotent stem cells. Aging (Albany NY). 2016;8(5):945–957.

119.

Kawala

Bohndorf

Graffmann

Wruck

Zatloukal

Adjaye

. Characterization of dermal fibroblast-derived iPSCs from a patient with low grade steatosis. Stem Cell Res. 2016;17(3):547–549.

120.

Kim

Jeong

Lee

Gweon

Ahn

Kim

Chung

. Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC. Exp Mol Med. 2016;48(6):e237.

121.

Pires

Nielsen

Waldemar

Hjermind

Nielsen

Dinnyes

Holst

Hyttel

Freude

. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer’s disease patient carrying a M146I mutation in PSEN1. Stem Cell Res. 2016;16(2):334–337.

122.

Pires

Nielsen

Waldemar

Hjermind

Nielsen

Dinnyes

Hyttel

Freude

. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer’s disease patient carrying an A79 V mutation in PSEN1. Stem Cell Res. 2016;16(2):229–232.

123.

Poon

Pires

Nielsen

Holst

Dinnyes

Hyttel

Freude

. Derivation of induced pluripotent stem cells from a familial Alzheimer’s disease patient carrying the L282F mutation in presenilin 1. Stem Cell Res.2016;17(3):470–473.

124.

Tubsuwan

Pires

Rasmussen

Schmid

Nielsen

Hjermind

Hall

Nielsen

Waldemar

Hyttel

Clausen

, et al. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer’s disease patient carrying a L150P mutation in PSEN-1. Stem Cell Res. 2016;16(1):110–112.

125.

Fidan

Kavaklıoğlu

Ebrahimi

Özlü

Ruacan

Gül

Önder

. Generation of integration-free induced pluripotent stem cells from a patient with Familial Mediterranean Fever (FMF). Stem Cell Res. 2015;15(3):694–696.

126.

Luo

Zhu

Gong

Xie

Fan

Sun

Chen

. Uniparental disomy of the entire X chromosome in Turner syndrome patient-specific induced pluripotent stem cells. Cell Discov. 2015;1:15022.

127.

Howden

Maufort

Duffin

Elefanty

Stanley

Thomson

. Simultaneous reprogramming and gene correction of patient fibroblasts. Stem Cell Reports. 2015;5(6):1109–1118.

128.

McLenachan

Zhang

Chen

Lamey

Thompson

McLaren

De Roach

Fletcher

Chen

. Generation of two induced pluripotent stem cell lines from a patient with dominant PRPF31 mutation and a related non-penetrant carrier. Stem Cell Res. 2019;101357.

129.

Bell

Peng

Crapper

Kolobova

Maussion

Vasuta

Yerko

Wong

Ernst

. A rapid pipeline to model rare neurodevelopmental disorders with simultaneous CRISPR/Cas9 gene editing. Stem Cells Transl Med. 2017;6(3):886–896.

130.

Briggs

Sun

Shepherd

Ovchinnikov

Chung

Nayler

Kao

Morrow

Thakar

Soo

Peura

, et al. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. Stem Cells. 2013;31(3):467–478.

131.

Mahairaki

Ryu

Peters

Chang

Park

Burridge

Talbot

Jr Asnaghi

Martin

Zambidis

, et al. Induced pluripotent stem cells from familial Alzheimer’s disease patients differentiate into mature neurons with amyloidogenic properties. Stem Cells Dev. 2014;23(24):2996–3010.

132.

Ramakrishnan

Yang

Tien

McKinley

Bocard

Maijub

Burchell

Williams

Morris

Hoying

Wade-Martins

, et al. Restoration of physiologically responsive low-density lipoprotein receptor-mediated endocytosis in genetically deficient induced pluripotent stem cells. Sci Rep. 2015;5:13231.

133.

Piao

Hung

Lim

Wong

. Efficient generation of integration-free human induced pluripotent stem cells from keratinocytes by simple transfection of episomal vectors. Stem Cells Transl Med. 2014;3(7):787–791.

134.

Dowey

Huang

Chou

Cheng

. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. Nat Protoc. 2012;7(11):2013–2021.

135.

Kamath

Ternes

McGowan

Moy

. Virus-free and oncogene-free induced pluripotent stem cell reprogramming in cord blood and peripheral blood in patients with lung disease. Regen Med. 2018;13(8):889–915.

136.

Wen

Cheng

Meng

Zhang

Yang

Zhang

Botimer

, et al. High-level precise knockin of iPSCs by simultaneous reprogramming and genome editing of human peripheral blood mononuclear cells. Stem Cell Reports. 2018;10(6):1821–1834.

137.

Wen

Zhang

Neises

Yuan

Cheng

Zhang

. Enhanced generation of integration-free iPSCs from human adult peripheral blood mononuclear cells with an optimal combination of episomal vectors. Stem Cell Reports. 2016;6(6):873–884.

138.

Wang

Zhang

Yang

Zhao

Liu

Lei

. Generation of a human control PBMC derived iPS cell line TUSMi001-A from a healthy male donor of Han Chinese genetic background. Stem Cell Res. 2017;25:22–25.

139.

Wang

Zhang

Huang

Zhao

Lei

. Generation of a human induced pluripotent stem cell line from a 65-year old healthy female donor with Chinese Han genetic background. Stem Cell Res. 2017;24:33–35.

140.

Neises

Zhang

. Generation of iPS cells from human peripheral blood mononuclear cells using episomal vectors. Methods Mol Biol. 2016;1357:57–69.

141.

Tangprasittipap

Jittorntrum

Wongkummool

Kitiyanant

Tubsuwan

. Generation of induced pluripotent stem cells from peripheral blood CD34+ hematopoietic progenitors of a 31 year old healthy woman. Stem Cell Res. 2017;20:91–93.

142.

Mack

Kroboth

Rajesh

Wang

. Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors. PLoS One. 2011;6(11):e27956 .

143.

Chou

Gao

Dowey

Wang

Shi

Cheng

. A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach. Stem Cells Transl Med. 2015;4(4):320–332.

144.

Weng

Kong

Ren

Karakikes

Geng

Chow

Mok

Chan

Keung

, et al. A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. Stem Cells Dev. 2014;23(14):1704–1716.

145.

Liu

Brzeszczynska

Samuel

Black

Palakkan

Anderson

Gallagher

Ross

. Efficient episomal reprogramming of blood mononuclear cells and differentiation to hepatocytes with functional drug metabolism. Exp Cell Res. 2015;338(2):203–213.

146.

TheinHan

Liu

Tang

Chen

Cheng

. Induced pluripotent stem cell-derived mesenchymal stem cell seeding on biofunctionalized calcium phosphate cements. Bone Res. 2013;4:371–384.

147.

Wang

Zhang

Lei

Zhao

. Establishment of TUSMi008-A, an induced pluripotent stem cell (iPSC) line from a 76-year old Alzheimer’s disease (AD) patient with PAXIP1 gene mutation. Stem Cell Res. 2019;36:101391.

148.

Wang

Zhang

Lei

Zhao

. Establishment of TUSMi007-A, an induced pluripotent stem cell (iPSC) line from an 83-year old Chinese Han patient with Alzheimer’s disease (AD). Stem Cell Res. 2018;33:265–268.

149.

Wang

Zhang

Chen

Sun

Meng

Lei

Zhao

. Establishment of TUSMi003-A, an induced pluripotent stem cell (iPSC) line from a 62-year old Chinese Han patient with Alzheimer’s disease with ApoE3/4 genetic background. Stem Cell Res. 2018;27:57–60.

150.

Wang

Chen

Lei

Zhao

. Derivation of induced pluripotent stem cells TUSMi006 from an 87-year old Chinese Han Alzheimer’s disease patient carrying GRINB and SORL1 mutations. Stem Cell Res. 2018;31:127–130.

151.

Wang

Fen

Qiu

Lei

Zhao

. Establishment of TUSMi005-A, an induced pluripotent stem cell (iPSC) line from a 32-year old Chinese Han patient with Bipolar Disorder (BD). Stem Cell Res. 2018;33:65–68.

152.

Wang

Kang

Fen

Lei

Zhao

. Establishment of TUSMi004-A, an induced pluripotent stem cell (iPSC) line from a 32-year old Chinese Han patient with Obsessive-Compulsive Disorder (OCD). Stem Cell Res. 2018;32:83–86.

153.

Zhao

Shi

Liu

. Generation of CSi001-A, a transgene-free, induced pluripotent stem cell line derived from a Parkinson Disease (PD) patient. Stem Cell Res. 2018;33:1–5.

154.

Murakami

Ishikawa

Kondo

Imamura

Tsukita

Enami

Funayama

Shibukawa

Matsumoto

Izumi

Ohta

, et al. Establishment of DYT5 patient-specific induced pluripotent stem cells with a GCH1 mutation. Stem Cell Res. 2017;24:36–39.

155.

Ross

Fraser

Nowak

Semsarian

. Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene. Stem Cell Res. 2017;20:88–90.

156.

Junqueira Reis

Picanço-Castro

Paes

BCMF

Pereira

Gerdes Gyuricza

de Araújo

Morato-Marques

Moreira

Costa

EBO

Dos Santos

TPM

Covas

, et al. Induced pluripotent stem cell for the study and treatment of sickle cell anemia. Stem Cells Int. 2017;2017:7492914.

157.

Malecki

Putzer

Sabo

Foorohar

Quach

Stampe

Beauchaine

Malecki

Tombokan

Anderson

. Directed cardiomyogenesis of autologous human induced pluripotent stem cells recruited to infarcted myocardium with bioengineered antibodies. Mol Cell Ther. 2014;2:13.

158.

Tang

Chen

Liu

Weir

Cheng

. Human induced pluripotent stem cell-derived mesenchymal stem cell seeding on calcium phosphate scaffold for bone regeneration. Tissue Eng Part A. 2014;20(7-8):1295–1305.

159.

Hsu

Reilly

Hayes

Clough

Konnick

Torok-Storb

Gulsuner

Becker

Keel

Abkowitz

, et al. Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. Blood. 2019;134(2):186–198.

160.

Slukvin

. Generation of transgene-free iPSC lines from human normal and neoplastic blood cells using episomal vectors. Methods Mol Biol. 2013;997:163–176.

161.

Varga

Hansen

Wüst

von Lindern

van den Akker

. Generation of human erythroblast-derived iPSC line using episomal reprogramming system. Stem Cell Res. 2017;25:30–33.

162.

Bhatt

Ghosh

Roy

Gao

Armanios

Cheng

Franco

. Robust reprogramming of Ataxia-Telangiectasia patient and carrier erythroid cells to induced pluripotent stem cells. Stem Cell Res. 2016;17(2):296–305.

163.

Bhatt

Ghosh

Roy

Gao

Armanios

Cheng

Franco

. Integration-free erythroblast-derived human induced pluripotent stem cells (iPSCs) from an individual with Ataxia-Telangiectasia (A-T). Stem Cell Res. 2016;17(2):205–207.

164.

Baylink

Neises

Kiroyan

Meng

Payne

Tschudy-Seney

Duan

Appleby

Kearns-Jonker

Gridley

, et al. Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors. PLoS One. 2013;8(5):e64496.

165.

Fernandes

Tembe

Singh

Vardhan

Nair

Kale

Limaye

. Development and characterization of human iPSC line NCCSi004-A from umbilical cord blood (UCB) derived CD34(+)cells obtained from donor belonging to Indian ethnic population. Stem Cell Res. 2019;35:101392.

166.

Fernandes

Shinde

Khan

Singh

Vardhan

Nair

Kale

Limaye

. Derivation of human iPSC line NCCSi002-A from umbilical cord blood (UCB) CD34+cells of donor from Indian ethnicity. Stem Cell Res. 2018;26:80–83.

167.

Fernandes

Talwadekar

Agarwal

Nair

Kale

Limaye

. Generation and characterization of human iPSC line from CD34(+) cells isolated from umbilical cord blood belonging to Indian origin. Stem Cell Res. 2017;18:60–63.

168.

Slamecka

Salimova

McClellan

van Kelle

Kehl

Laurini

Cinelli

Owen

Hoerstrup

Weber

. Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions. Cell Cycle. 2016;15(2):234–249.

169.

Kang

Song

Huang

Wang

Sun

Fan

. Defining differentially methylated regions specific for the acquisition of pluripotency and maintenance in human pluripotent stem cells via microarray. PLoS One. 2014;9(9):e108350.

170.

Wilson

Payne

. Genetic reprogramming of human amniotic cells with episomal vectors: neural rosettes as sentinels in candidate selection for validation assays. PeerJ. 2014;2:e668.

171.

Xing

Cui

Luan

Zhou

Shi

Han

. Establishment of a human trisomy 18 induced pluripotent stem cell line from amniotic fluid cells. Intractable Rare Dis Res. 2018;7(2):94–99.

172.

Slamecka

McClellan

Wilk

Laurini

Manci

Hoerstrup

Weber

Owen

. Induced pluripotent stem cells derived from human amnion in chemically defined conditions. Cell Cycle. 2018;17(3):330–347.

173.

Göbel

Goetzke

Eggermann

Wagner

. Interrupted reprogramming into induced pluripotent stem cells does not rejuvenate human mesenchymal stromal cells. Sci Rep. 2018;8(1):11676.

174.

Foja

Jung

Harwardt

Riemann

Pelz-Ackermann

Schroeder

. Hypoxia supports reprogramming of mesenchymal stromal cells via induction of embryonic stem cell-specific microRNA-302 cluster and pluripotency-associated genes. Cell Reprogram. 2013;15(1):68–79.

175.

Liu

Song

. Induced pluripotent stem cells generated from human adipose-derived stem cells using a non-viral polycistronic plasmid in feeder-free conditions. PLoS One. 2012;7(10):e48161.

176.

Thekkeparambil Chandrabose

Sriram

Subramanian

Cheng

Ong

Rozen

Kasim

NHA

Sugii

. Amenable epigenetic traits of dental pulp stem cells underlie high capability of xeno-free episomal reprogramming. Stem Cell Res Ther. 2018;9(1):68.

177.

Saitoh

Inada

Iwase

Noguchi

Murakami

Soda

Kubota

Hasegawa

Akasaka

Matsumoto

Oka

, et al. Choice of feeders is important when first establishing iPSCs derived from primarily cultured human deciduous tooth dental pulp cells. Cell Med. 2015;8(1-2):9–23.

178.

Yan

Meng

Wang

Yuan

Wang

. Generation of induced pluripotent stem cells from human mesenchymal stem cells of parotid gland origin. Am J Transl Res. 2016;8(2):419–432.

179.

Schröter

Sleegers

Bohndorf

Wruck

Van Broeckhoven

Adjaye

. Lymphoblast-derived integration-free iPS cell line from a 69-year-old male. Stem Cell Res. 2016;16(1):29–31.

180.

Barrett

Ornelas

Yeager

Mandefro

Sahabian

Lenaeus

Targan

Svendsen

Sareen

. Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines. Stem Cells Transl Med. 2014;3(12):1429–1434.

181.

Schröter

Sleegers

Cuyvers

Bohndorf

Wruck

Van Broeckhoven

Adjaye

. Lymphoblast-derived integration-free iPS cell line from a female 67-year-old Alzheimer’s disease patient with TREM2 (R47 H) missense mutation. Stem Cell Res. 2016;17(3):553–555.

182.

Zulfiqar

Fritz

Nieweg

. Episomal plasmid-based generation of an iPSC line from a 79-year-old individual carrying the APOE4/4 genotype: i11001. Stem Cell Res. 2016;17(3):544–546.

183.

Zulfiqar

Fritz

Nieweg

. Episomal plasmid-based generation of an iPSC line from an 83-year-old individual carrying the APOE4/4 genotype: i10984. Stem Cell Res. 2016;17(3):523–525.

184.

Schröter

Sleegers

Van Cauwenberghe

Bohndorf

Wruck

Van Broeckhoven

Adjaye

. Lymphoblast-derived integration-free iPSC lines from a female and male Alzheimer’s disease patient expressing different copy numbers of a coding CNV in the Alzheimer risk gene CR1. Stem Cell Res. 2016;17(3):560–563.

185.

Schröter

Sleegers

Cuyvers

Bohndorf

Wruck

Van Broeckhoven

Adjaye

. Lymphoblast-derived integration-free iPS cell line from a 65-year-old Alzheimer’s disease patient expressing the TREM2 p.R47 H variant. Stem Cell Res. 2016;16(1):113–115.

186.

Martins

Bohndorf

Schröter

Assar

Wruck

Sleegers

Van Broeckhoven

Adjaye

. Lymphoblast-derived integration-free ISRM-CON9 iPS cell line from a 75year old female. Stem Cell Res. 2018;26:76–79.

187.

Fujimori

Tezuka

Ishiura

Mitsui

Doi

Yoshimura

Tada

Matsumoto

Isoda

Hashimoto

Hattori

, et al. Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines. Mol Brain. 2016;9(1):88.

188.

Howard-Jones

Cheung

Glen

Allen

Stephens

. Integration-free reprogramming of lamina propria progenitor cells. J Dent Res. 2016;95(8):882–888.

189.

Alvisi

Trevisan

Masi

Canel

Caenazzo

Nespeca

Barzon

Di Iorio

Barbaro

Palù

. Generation of a transgene-free human induced pluripotent stem cell line (UNIPDi001-A) from oral mucosa epithelial stem cells. Stem Cell Res. 2018;28:177–180.

190.

Trevisan

Di Iorio

Masi

Riccetti

Barzon

Alvisi

Caenazzo

Barbaro

Palù

. Induced pluripotent stem cells line (UNIPDi003-A) from a patient affected by EEC syndrome carrying the R279 H mutation in TP63 gene. Stem Cell Res. 2018;28:141–144.

191.

Wang

Chen

Guan

Zhao

Yang

Wang

Yang

Song

, et al. Using low-risk factors to generate non-integrated human induced pluripotent stem cells from urine-derived cells. Stem Cell Res Ther. 2017;8(1):245.

192.

Si-Tayeb

Idriss

Champon

Caillaud

Pichelin

Arnaud

Lemarchand

Le May

Zibara

Cariou

. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis Model Mech. 2016;9(1):81–90.

193.

Guo

Liu

Gao

Kou

Yang

Abbas

Zhou

Cai

Zhang

Qin

, et al. Generation of non-integrated induced pluripotent stem cells from a 59-year-old female with multiple endocrine neoplasia type 1 syndrome. Stem Cell Res. 2017;18:64–66.

194.

Jouni

Si-Tayeb

Es-Salah-Lamoureux

Latypova

Champon

Caillaud

Rungoat

Charpentier

Loussouarn

Baró

Zibara

, et al. Toward personalized medicine: using cardiomyocytes differentiated from urine-derived pluripotent stem cells to recapitulate electrophysiological characteristics of type 2 long QT syndrome. J Am Heart Assoc. 2015;4(9):e002159.

195.

Steichen

Si-Tayeb

Wulkan

Crestani

Rosas

Dariolli

Pereira

Krieger

. Human Induced Pluripotent Stem (hiPS) cells from urine samples: a non-integrative and feeder-free reprogramming strategy. Curr Protoc Hum Genet. 2017;92:21.7.1–21.7.22.

196.

Wang

Qiao

Hei

. Exosomes from iPSCs delivering siRNA attenuate intracellular adhesion molecule-1 expression and neutrophils adhesion in pulmonary microvascular endothelial cells. Inflammation. 2017;40(2):486–496.

197.

Cui

Shi

Luan

Zhou

Han

. Generation of urine-derived induced pluripotent stem cells from a patient with phenylketonuria. Intractable Rare Dis Res. 2018;7(2):87–93.

198.

Zhou

Qiu

Zhou

Feng

Zeng

Sun

Liu

, et al. Seamless genetic conversion of SMN2 to SMN1 via CRISPR/Cpf1 and single-stranded oligodeoxynucleotides in spinal muscular atrophy patient-specific induced pluripotent stem cells. Hum Gene Ther. 2018;29(11):1252–1263.

199.

Bohndorf

Ncube

Spitzhorn

Enczmann

Wruck

Adjaye

. Derivation and characterization of integration-free iPSC line ISRM-UM51 derived from SIX2-positive renal cells isolated from urine of an African male expressing the CYP2D6 *4/*17 variant which confers intermediate drug metabolizing activity. Stem Cell Res. 2017;25:18–21.

200.

Paulitschek

Schulze-Matz

Hesse

Schmidt

Wruck

Adjaye

Schrader

. Generation and characterization of two iPSC lines from human epicardium-derived cells. Stem Cell Res. 2017;20:50–53.

201.

Diecke

Lee

Termglinchan

Kooreman

Burridge

Ebert

Churko

Sharma

Kay

. Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. Sci Rep. 2015;5:8081.

202.

Ikeda

Mizoro

Ameku

Nomiya

Mae

Matsui

Kuchitsu

Suzuki

Hamaoka-Okamoto

Yahata

Sone

, et al. Transcriptional analysis of intravenous immunoglobulin resistance in Kawasaki disease using an induced pluripotent stem cell disease model. Circ J. 2016;81(1):110–118.

203.

Cheng

Hansen

Zhao

Zou

Donovan

Chou

Zhou

Dowey

, et al. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell. 2012;10(3):337–344.

204.

Park

Huo

Peters

Talbot

Jr Verma

Zimmerlin

Kaplan

Zambidis

. Growth factor-activated stem cell circuits and stromal signals cooperatively accelerate non-integrated iPSC reprogramming of human myeloid progenitors. PLoS One. 2012;7(8):e42838.

205.

Park

Bhutto

Zimmerlin

Huo

Nagaria

Miller

Rufaihah

Talbot

Aguilar

Grebe

Merges

, et al. Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. Circulation. 2014;129(3):359–372.

206.

Song

Awari

Han

Uche-Anya

Park

Yabe

Chung

Yazawa

. Dual optical recordings for action potentials and calcium handling in induced pluripotent stem cell models of cardiac arrhythmias using genetically encoded fluorescent indicators. Stem Cells Transl Med. 2015;4(5):468–475.

207.

Zhao

Davies

Ning

Chang

Sachamitr

Sattler

Fairchild

Huang

. A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors. Cell Reprogram. 2015;17(1):7–18.

208.

Park

Noh

Chung

Kang

Kim

Park

. Efficient generation of virus-free iPS cells using liposomal magnetofection. PLoS One. 2012;7(9):e45812.

209.

Cao

Xie

Gollan

Zhao

Narsinh

Lee

. Comparison of gene-transfer efficiency in human embryonic stem cells. Mol Imaging Biol. 2010;12(1):15–24.

210.

Tomizawa

Shinozaki

Motoyoshi

Sugiyama

Yamamoto

Sueishi

. Dual gene expression in embryoid bodies derived from human induced pluripotent stem cells using episomal vectors. Tissue Eng Part A. 2014;20(23-24):3154–3162.

211.

Shiba

Gomibuchi

Seto

Wada

Ichimura

Tanaka

Ogasawara

Okada

Shiba

Sakamoto

Ido

, et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature. 2016;538(7625):388–391.

212.

Loh

Wang

Kao

Cardona

Chuang

Wei

. Episomal induced pluripotent stem cells promote functional recovery of transected murine peripheral nerve. PLoS One. 2016;11(10):e0164696.

213.

Liu

Hsu

Chang

Lee

Liu

Chien

Lin

Shyu

. Mouse-induced pluripotent stem cells generated under hypoxic conditions in the absence of viral infection and oncogenic factors and used for ischemic stroke therapy. Stem Cells Dev. 2014;23(4):421–433.

214.

Wang

Wen

Wei

Green

Wani

Zhang

Pera

Chen

. Smooth muscle precursor cells derived from human pluripotent stem cells for treatment of stress urinary incontinence. Stem Cells Dev. 2016;25(6):453–461.

215.

Kamao

Mandai

Okamoto

Sakai

Suga

Sugita

Kiryu

Takahashi

. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports. 2014;2(2):205–218.

216.

Cell Engineering Division / RIKEN BioResource Research Center. 2016. [accessed May 23]. https://www.newscientist.com/article/dn27986/.

217.

Trounson

DeWitt

. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17(3):194–200.

218.

Garber

. Inducing translation. Nat Biotechnol. 2013;31(6):483–486.

219.

Daley

Hyun

Apperley

Barker

Benvenisty

Bredenoord

Breuer

Caulfield

Cedars

Frey-Vasconcells

Heslop

, et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. Stem Cell Reports. 2016;6(6):787–797.

220.

Health / New Scientist. 2015. [July 31]. http://cell.brc.riken.jp/en/hps/search_hps_en.

221.

Takahashi

Tanabe

Ohnuki

Narita

Ichisaka

Tomoda

Yamanaka

. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872.

222.

Nakagawa

Koyanagi

Tanabe

Takahashi

Ichisaka

Aoi

Okita

Mochiduki

Takizawa

Yamanaka

. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008;26(1):101–106.

223.

Zhao

Zhang

Westenskow

Todorova

Lin

Rong

Kim

Wang

Clegg

, et al. Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell. 2015;17(3):353–359.

224.

Xiao

Takahashi

Tan

. Induced pluripotent stem cells in Parkinson’s disease: scientific and clinical challenges. J Neurol Neurosurg Psychiatry. 2016;87(7):697–702.